Schwab Charles Investment Management Inc. increased its position in Heron Therapeutics Inc (NASDAQ:HRTX) by 50.7% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 242,934 shares of the biotechnology company’s stock after acquiring an additional 81,735 shares during the period. Schwab Charles Investment Management Inc. owned about 0.38% of Heron Therapeutics worth $4,398,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Trexquant Investment LP bought a new stake in shares of Heron Therapeutics during the 3rd quarter valued at $206,000. Jane Street Group LLC purchased a new position in shares of Heron Therapeutics during the 3rd quarter valued at $223,000. Parametric Portfolio Associates LLC lifted its stake in shares of Heron Therapeutics by 2.3% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 33,910 shares of the biotechnology company’s stock valued at $470,000 after buying an additional 771 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Heron Therapeutics by 30.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 34,741 shares of the biotechnology company’s stock valued at $482,000 after buying an additional 8,135 shares in the last quarter. Finally, Royce & Associates LP lifted its stake in shares of Heron Therapeutics by 17.4% during the 3rd quarter. Royce & Associates LP now owns 67,500 shares of the biotechnology company’s stock valued at $1,090,000 after buying an additional 10,000 shares in the last quarter.
Shares of NASDAQ HRTX traded down $1.15 during trading on Friday, hitting $26.75. The company had a trading volume of 1,547,206 shares, compared to its average volume of 1,972,856. Heron Therapeutics Inc has a fifty-two week low of $12.70 and a fifty-two week high of $32.70. The firm has a market cap of $1,888.79, a price-to-earnings ratio of 7.33 and a beta of 1.88.
Heron Therapeutics (NASDAQ:HRTX) last announced its earnings results on Tuesday, February 27th. The biotechnology company reported ($1.09) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.80) by ($0.29). The company had revenue of $10.05 million during the quarter, compared to analyst estimates of $9.00 million. Heron Therapeutics had a negative net margin of 641.87% and a negative return on equity of 230.70%. equities analysts expect that Heron Therapeutics Inc will post -2.5 EPS for the current fiscal year.
In other Heron Therapeutics news, Director Kevin C. Tang purchased 192,308 shares of the firm’s stock in a transaction dated Thursday, March 29th. The shares were purchased at an average cost of $26.00 per share, with a total value of $5,000,008.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Kimberly Manhard sold 7,584 shares of the firm’s stock in a transaction dated Wednesday, January 10th. The stock was sold at an average price of $20.00, for a total transaction of $151,680.00. Following the completion of the transaction, the vice president now directly owns 7,584 shares in the company, valued at $151,680. The disclosure for this sale can be found here. Over the last three months, insiders sold 225,584 shares of company stock worth $6,141,680. Insiders own 19.93% of the company’s stock.
HRTX has been the topic of several analyst reports. Lake Street Capital set a $42.00 price target on shares of Heron Therapeutics and gave the company a “buy” rating in a report on Thursday. Noble Financial restated a “buy” rating on shares of Heron Therapeutics in a research note on Wednesday, March 21st. BidaskClub cut shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Cantor Fitzgerald set a $40.00 price target on shares of Heron Therapeutics and gave the stock a “buy” rating in a report on Monday, March 19th. Finally, Cowen reaffirmed a “buy” rating on shares of Heron Therapeutics in a report on Monday, March 19th. One equities research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $35.92.
TRADEMARK VIOLATION NOTICE: This news story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/08/schwab-charles-investment-management-inc-has-4-40-million-stake-in-heron-therapeutics-inc-hrtx.html.
Heron Therapeutics Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.